Metallo beta lactamases in Pseudomonas aeruginosa and acinetobacter species

Expert Opinion on Investigational Drugs

Volumn 17, Issue 2, 2008, Pages 131-143

  Gupta, Varsha ^a  

^a GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Acinetobacter species; Metallo beta lactamases; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COLISTIMETHATE; COLISTIN; DNA; DORIPENEM; DOXYCYCLINE; ERTAPENEM; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PENICILLIN G; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ACINETOBACTER; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AUSTRALIA; BACTERIAL GENETICS; DNA PROBE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME STRUCTURE; ENZYME SYNTHESIS; EPIDEMIOLOGICAL DATA; FALSE POSITIVE RESULT; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; KIDNEY DISEASE; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEUROLOGIC DISEASE; NEUROMUSCULAR BLOCKING; NONHUMAN; PATIENT MONITORING; PHENOTYPE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; X RAY CRYSTALLOGRAPHY; ANIMAL; BACTERIAL INFECTION; CLASSIFICATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 39049134890     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.2.131     Document Type: Review

References (161)

1. Medeiros AA. Evolution and dissemination of beta lactamases accelerated by generation of beta lactam antibiotics. Clin Infect Dis 1997;24:S19-45
2. Gniadkowski M. Evolution and epidemiology of extended spectrum beta-lactamases (ESBLs) and ESBL-producing micoorganisms. Clin Microbiol Infect 2001;7(11);597-608
3. Hsueh PR, Teng LJ, Chen CY, et al. Pandrug resistant Acinetobacter baumanii causing nosocomial infections in a university hospical, Taiwan. Emerg Infect Dis 2002;8:827-32
4. Walsh TR, Tolemann MA, Poirel L, Nordmann P. Metallo beta lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18(2):306-25
5. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000;3:489-95
6. Docquier JD, Lamotte Brasseur J, Galleni M, Amiconsate G, Frere JM, Rossolini GM. On functional and structural heterogeneity of VIM-type metallo-β-lactamases. J Antimicrob Chemother 2003;51:257-66
7. Ambler RP. The structure of β-lactamases. Phil Trans R Soc Lond B Biol Sci 1980;289:321-31
8. Bush K. Classification of β-lactamases - group-2c, group-2d, group-2e, group-3, and group-4. Antimicrob Agents Chemother 1989;33:271-6
9. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33
10. Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 1997,41:223-32
11. Hussain M, Carlino A, Madonna MJ, Lampen O. Cloning and sequencing of the metallothioprotein β-lactamase II gene of Bacillus cereus 569H in Escherichia coli. J Bacteriol 1985;164:223-9
12. Kato C, Kudo, T, Watanabe K, Horikoshi K. Nucleotide sequence of the beta-lactamase gene of alkalophilic Bacillus sp. strain 170. J Gen Microbiol 1985;131:3317-24
13. Lim HM, Pene JJ, Shaw RW. Cloning, nucleotide sequence, and expression of the Bacillus cereus 5/B/6 beta-lactamase II structural gene. J Bacteriol 1988;170:2873-8
14. Rasmussen BA, Gluzmann Y, Tally FP. Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother 1990;34:1590-2
15. Bellais S, Aubert D, Naas T, Nordmann P. Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing β-lactamases in Chryseobactcrium meningosepticum. Antimicrob Agents Chemother 2000;44:1873-86
16. Rossolini GM, Franceschini N, Riccio ML, et al. Characterization and sequence of the Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B beta-lactamase showing a broad substrate profile. Biochem J 1998;332:145-52
17. Bellais S, Leatard S, Poirel L, Naas T, Nordmann P. Molecular characterization of a carbapenem-hydrolyzipg beta-lactamase from Chryseobacterium (Flavobacterium) indologenes. FEMS Microbiol Lett 1999;171:127-32
18. Laraki N, Galleni M, Thamm I, et al. Structure of In31, a blaIMP-containing P. aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes. Antimicrob Agents Chemother 1999;43:890-901
19. Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-beta-lactamase-producing P. aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother 1996;40:349-53
20. Osano E, Arakawa Y, Wacharotayankun R, et al. Molecular characterization of an enterobacterial metallo-β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother 1994;8:71-8
21. Riccio ML, Franceschini N, Boschi L, et al. Characterization of the metallo-beta-lactamase determinant of Acinetobacter baumannii AC-54/97 reveals the existence of bla(IMP) allele variants carried by gene cassettes of different phylogeny. Antimicrob Agents Chemother 2000;44:1229-35
22. VIM, a new integron-borne metallo-β-lactamase gene from a P. aeruginosa clinical isolate. Antimicrob Agents Chemother 1999; 43:1584-90
23. Poirel L, Naas T, Nicolas D, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a P. aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000;44:891-7
24. Massida O, Rossolini GM, Satta G. The Aeromonas hydrophila cphA gene: molecular heterogeneity among class B metallo-β-lactamases. J Bacteriol 1991;173:4611-7
25. Sanchagrin F, Dufresne J, Levesque RC. Molecular heterogeneity of the L-1 metallo-β-lactamase family from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1998;42:1245-8
26. Boschi L, Mercuri PS, Riccio ML, et al. The Legionella (Fluoribacter) gormanii metallo-β-lactamase: a new member of the highly divergent lineage of molecular-subclass B3 β-lactamase. Antimicrob Agents Chemother 2000;44:1538-43
27. Carfi A, Pares S, Duee E, et al. The 3-D structure of a zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein fold. EMBO J 1995;14(20):4914-21
28. Fabiane SM, Sohi MK, Wan T, et al. Crystal structure of the zinc-dependent beta-lactamase from Bacillus cereus at 1.9 A resolution: binuclear active site with features of a mononuclear enzyme. Biochemistry 1998;37(36):12404-11
29. Ullah JH, Walsh TR, Taylor IA, et al. The crystal structure of the L1 metallo-beta-lactamase from Stenotrophomonas maltophilia at 1.7 A resolution. J Mol Biol 1998;284(1):125-36
30. de Seny D, Heinz U, Wommer S, et al. Metal ion binding and coordination geometry for wild type and mutants of metallo-beta -lactamase from Bacillus cereus 569/H/9 (BcII): a combined thermodynamic, kinetic, and spectroscopic approach. J Biol Chem 2001;276(48):45065-78
31. Hernandez Villadares M, Felici A, Weber G, et al. Zn(II) dependence of the Aeromonas hydrophila AE036 metallo-beta-lactamase activity and stability. Biochemistry 1997;36(38):11534-41
32. Garau G, Bebrone C, Anne C, Galleni M, Frere JM, Dideberg O. A metallo-beta-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. J Mol Biol 2005;345(4):785-95
33. Wang Z, Fast W, Valentine AM, Benkovic SJ. Metallo-beta-lactamase: structure and mechanism. Curr Opin Chem Biol 1999;3(5):614-22
34. Xu D, Xie D, Guo H. Catalytic mechanism of class B2 metallo-beta-lactamase. J Biol Chem 2006;281(13):8740-7
35. Carfi A, Duee E, Paul-Soto R, Galleni M, Frere JM, Dideberg O. X-ray structure of the ZnII beta-lactamase from Bacteroides fragilis in an orthorhombic crystal form. Acta Crystallogr Sect D 1998;54:45-57
36. Concha NO, Rasmussen BA, Bush K, Herzberg O. Crystal structure of the wide-spectrum binuclear zinc β-lactamase from Bacteroides fragilis. Structure 1996;4:823-36
37. Concha NO, Janson CA, Rowling P, et al. Crystal structure of the IMP-1 metallo beta-lactamase from P. aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. Biochemistry 2000;39:4288-98
38. Galleni M, Lamotte-Brasseur J, Rossolini GM, Spencer J, Dideberg O, Frere JM. Standard numbering scheme for class B beta-lactamases. Antimicrob Agents Chemother 2001;45:660-3
39. Garau G, Garcia-Saez I, Bebrone C, et al. Update of the standard numbering scheme for class B β-lactamases. Antimicrob Agents Chemother 2004;48(7):2347-9
40. Chen YH, Succi J, Tenover FC, Koehler TM. β-Lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain. J Bacteriol. 2003;185:823-30
41. Gales AC, Tognim MC, Reis AO, Jones RN, Sader HS. Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. Diagn Microbiol Infect Dis 45:77-9
42. Rossolini GM, Condemi MA, Pantanella F, Docquier JD, Amicosante G, Thaller MC. Metallo-β-lactamase producers in environmental microbiota: new molecular class B enzyme in Janthinobacterium lividum. Antimicrob Agents Chemother 2001;45:837-44
43. Rasmussen BA, Kovacs E. Identification and DNA sequence of a new Bacteroides fragilis insertion sequence-like element. Plasmid 1991;25:141-4
44. Thompson JS, Malamy MH. Sequencing of the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus β-lactamase BCII. J Bacteriol 1990;172:2584-93
45. Podglajen I, Breuil J, Casin I, Collatz E. Genotypic identification of two groups within the species Bacteroides fragilis by ribotyping and by analysis of PCR-generated fragment patterns and insertion sequence content. J Bacteriol 1995;177:5270-5
46. Yamazoe K, Kato N, Kato H, Tanaka K, Katagiri Y, Watanabe K. Distribution of the cfiA gene among Bacteroides fragilis strains in Japan and relatedness of cfiA to imipenem resistance. Antimicrob Agents Chemother 1999;43:2808-10
47. Bennett PM. Integrons and gene cassettes: a genetic construction kit for bacteria. J Antimicrob Chemother 1999;43:1-4
48. Stokes HW, O'Gorman DB, Recchia GD, Parsekhian M, Hall RM. Structure and function of 59-base element recombination sites associated with mobile gene cassettes. Mol Microbiol 1997;26(4):731-45
49. Collis CM, Hall RM. Expression of antibiotic resistance genes in the integrated cassettes of integrons. Antimicrob Agents Chemother 1995;39(1):155-62
50. Fluit AC, Schmitz FJ. Class 1 integrons, gene cassettes, mobility, and epidemiology. Eur J Clin Microbiol Infect Dis 1999;18(11):761-70
51. Shibata N, Doi Y, Yamane K, Yaqui T. PCR typing of genetic determinants for metallo beta lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 2003;41(12):5407-13
52. Iwanaga M, Toma C, Miyazato T, Insisiengmay S, Nakasone N, Ehara M. Antibiotic resistance conferred by a class I integron and SXT constin in Vibrio cholerae 01 strains isolated in Laos. Antimicrob Agents Chemother 2004;48:2364-9
53. Partridge SR, Hall RM. The IS1111 family members IS4321 and IS5075 have subterminal inverted repeats and target the terminal inverted repeats of Tn21 family transposons. J Bacteriol 2003;185:6371-84
54. Toleman MA, Bennett PM, Walsh TR. ISCR elements: novel gene-capturing systems of the 21st century? Microbiol Mol Biol Rev 2006;70(2):296-316
55. Watanabe M, Iyobe S, Inoue M, Mirsuhashi S. Transferable imipenem resistance in P. aeruginosa. Antimicrob Agents Chemother 1991;35:147-51
56. Payne DJ, Cramp R, Bateson JH, Neale JD, Knowles J. Rapid identification of metallo- and serine β-lactamase. Antimicrob Agents Chemother 1994;38:991-6
57. Yamaguchi H, Nukuga M, Sawai T. Appearance of an R plasmid mediated metallo beta lactamase in gram negative enteric bacteria. DNA Data Base of JAPAN (DDBJ) enyrt name KPNRD4; accession number D29636
58. Kurokawa H, Yagi T, Shibata N, Shibayama K, Arakawa Y. World wide proliferation of carbapenem resistant gram negative bacteria. Lancet 1999;354(9182):955
59. Koh TH, Babini GS, Woodford N, Sng-LH, Hall LCM, Livermore DM. Carpapenem hydrolyzing IMP-1 beta lactamase in Klebsiella pneumoniae from Singapore. Lancet 1999;353:2162
60. Cornaglia G, Recio ML, Mazzaroil A, Leuretti L, Fontana R, Rossolini GN. Appearance of IMP-1 beta lactamase in Europe. Lancet 1999;353:899-900
61. Nordmann P, Poirel L. Emerging carbapenemases in gram negative aerobes. Clin Microbiol Infect 2002;8:321-31
62. VIM-1-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother 2001;45:1249-53
63. Lombardi G, Luzzaro F, Doquier JD, et al. Nosocomial infections caused by multidrug-resistant isolates of Pseudomonas putida producing VIM-1 metallo-β-lactamase. J Clin Microbiol 2002;40:4051-5
64. VIM-1 metallo-β-lactamase gene. Diagn Microbiol Infect Dis 2004;48:167-72
65. Giakkoupi P, Xanthaki A, Kanelopoulou M, et al. VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 2003;41:3893-6
66. Poirel L, Collet L, Nordmann P. Carbapenem-hydrolyzing metallo-β-lactamase from a nosocomial isolate of P. aeruginosa in France. Emerg Infect Dis 2000;6:84-5
67. Cardoso O, Leitao R, Figueiredo A, Sousa JC, Duarte A, Peixe LV. Metallo-β-lactamase VIM-2 in clinical isolates of P. aeruginosa from Portugal. Microb Drug Resist 2002;8:93-7
68. Sardelic S, Pallecchi L, Punda-Polic V, Rossolini GM. Carbapenem-resistant P. aeruginosa-carrying VIM-2 metallo-β-lactamase determinants, Croatia. Emerg Infect Dis 2003; 9:1022-3
69. Yum JH, Yong D, Lee K, Kim HS, Chong Y. A new integron carrying VIM-2 metallo-β-lactamase gene cassette in a Serratia marcescens isolate. Diagn Microbiol Infect Dis 2002;42:217-9
70. Luzzaro F, Docquier JD, Colinon C, et al. Emergence in Klebsiella pneumoniae and Enterobacter cloacae clinical isolates of the VIM-4 metallo-β-lactamase encoded by a conjugative plasmid. Antimicrob Agents Chemother 2004;48:648-50
71. Toleman MA, Simm AM, Murphy TA, et al. Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2002;50:673-9
72. SPM-1-surrounding sequences from disseminated P. aeruginosa isolates in Recife, Brazil. Antimicrob Agents Chemother 2004;48:1406-9
73. Murphy TA, Simm AM, Toleman MA, Jones RN, Walsh TR. Biochemical characterization of the acquired metallo-β-lactamase SPM-1 from P. aeruginosa. Antimicrob Agents Chemother 2003;47:582-7
74. GIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob Agents Chemother 2004;8:4654-61
75. SIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 2005;4911:4485-91
76. Yong D, Bell JM, Ritchie B, Pratt R, Toleman MA, Walsh TR. A novel sub-group metallo-b-lactamase (MBL), AIM-1 emerges in Pseudomonas aeruginosa (PSA) from Australia
77. Franklin C. Liolios L. Peleg AY. Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory. J Clin Microbiol 2006;44(9):3139-44
78. Kim SY, Hong SG, Moland ES, Thomson KS. Convenient test using combination of chelating agents for detection of metallo-[beta]-lactamases in the clinical laboratory. J Clin Microbiol 2007;45(9):2798-801
79. Arakawa Y, Shibata N, Shibayama K, et al. Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol 2000;38(1):40-3
80. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003;41(10):4623-9
81. Yong D, Lee K, Yum JH, et al. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2002;40(10):3798-801
82. Yan JJ, Wu JJ, Tsai SH, Chuang CL. Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-beta-lactamases in gram-negative bacilli. Diagn Microbiol Infect Dis 2004;49(1):5-11
83. Walsh TR, Bolmstrom A, Qwarnstrom A, Gales A. Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical testing. J Clin Microbiol 2002;40(8):2755-9
84. Yan J, Wu JJ, Tsai SH, Chuang CL. Comparison of the double disk, combined disk, and Etest methods for detecting metallo beta lactamases in gram negative bacilli. Diagn Microbiol Infect Dis. 2004;49:5-11
85. Chu YW, Cheung TK, Ngan JY, Kam KM. EDTA susceptibility leading to false detection of metallo-beta-lactamase in Pseudomonas aeruginosa by Etest and an imipenem-EDTA disk method. Int J Antimicrob Agents 2005;26(4):340-1
86. Segal H, Elisha BG. Use of Etest MBL strips for the detection of carbapenemases in Acinetobacter baumannii. J Antimicrob Chemother 2005;56(3):598
87. Mendes RE, Kivota KA, Monteiro I, et al. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol 2007;45(2):544-7
88. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and P. aeruginosa. Clin Infect Dis 2006;43(1):S49-56
89. Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant P. aeruginosa. Antimicrob Agents Chemother 1992;36(9):2046-8
90. Paterson DL. Serious infections caused by enceric gram-negative bacilli - mechanisms of antibiotic resistance and implications for therapy of gram-negative sepsis in the transplanted patient. Semin Respir Infect 2002;17(4):260-4
91. Rossolini GM. Acquired metallo-beta-lactamases: an increasing clinical threat. Clin Infect Dis 2005;41(11):1557-8
92. Bellais S, Mimoz O, Leotard S, Jacolot A, Petitjean OP, Nordmann O. Efficacy of β-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-β-lactamase-producing strain of P. aeruginosa. Antimicrob Agents Chemother 2002;46:2032-4
93. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant P. aeruginosa. Clin Infect Dis 2003;37:E154-60
94. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant P. aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28(5):1008-11
95. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous Colistin. BMC Infect Dis 2005;5(1):1
96. Biancofiore G, Tascini C, Bisa M, et al. Colistin meropenem and rifampin in a combination therapy for multi-drug resistant A. baumanii multifocal infection. A case report. Minerva Anestesiol 2007;73(3);181-5
97. Zuravleff JJ, Yu VL, Yee RB. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triple combination against P. aeruginosa. J Lab Clin Med 1983;101:896-902
98. Zuravleff JJ, Chervenick P, Yu VL, Muder RR, Diven WF. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of P. aeruginosa infections: assessment in a neutropenic mouse model. J Lab Clin Med 1984;103:878-85
99. Korvick JA, Peacock JE Jr, Muder RR, Wheeler R, Yu VL. Addition of rifampin to combination antibiotic therapy for R aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob Agents Chemother 1992;36:620-5
100. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant R aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43:S95-9
101. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:753-7
102. Urban C, Go E, Mariano N, Rahal JJ. Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins imipenem-resistant and susceptible Acinetobacter baumannii. FEMS Microbiol Lett 1995;125:193-8
103. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004;38(9):1279-86
104. Mushtaq S, Ge Y, Livermore DM. Doripenem versus P. aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48(8):3086-92
105. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003;47(1):400-4
106. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004;48(11):4479-81
107. Tiengrim S, Tribuddharat C, Thamlikitkul V. In vitro activity of tigecycline against clinical isolates of multi-drug resistant A. baumanii in Siriraj Hospital, Thailand. J Med Assoc Thai 2006;89(Suppl 5):S102-5
108. Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-80
109. Zavascki AP, Goldani LZ, Li J, et al. Polymyxin B for the treatment of multi-drug resistant pathogens: a critical review. J Antimicrob Chemother 2007;60(6):1206-15
110. Betrosian AP, Frantzeskaki F, Xanthaki, et al. High dose ampicillin-sulbactum as alternative treatment of late onset VAP from multi-drug resistant A. baumanii. Scand J Infect Dis 2007;39(1):38-43
111. Koomanchai P, Tiengrim S, Kiratisin P, et al. efficacy and safety of Colistin for therapy of infections caused by multi-drug resistant Pseudomonas aeruginosa and A. baumanii in Siriraj Hospital, Thailand. Int J Infect Dis 2007;11(5):402-6
112. Hollaway KP, Rouphael NG, Wells JB, et al. Polymyxin B and doxycycline use in patients with multi-drug resistant A. baumanii infections in the intensive care unit. Ann Pharmacother 2006;40(11):1939-45
113. Ferrara AM. Potentially multidrug resistant non-fermentative gram-negative pathogens causing nosocomial pneumonia. Int J Antimicrob Agents 2006;27(3):183-95
114. Timurkaynak F, Can F, Azap OK, et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug resistant strains of P. aeruginosa and A. baumanii isolated from intensive care units. Int J Antimicrob Agents 2006;27(3):224-8
115. Kawa AL, Loh C, Low JG, et al. Nebulized Colistin in the treatment of pneumonia due to multidrug resistant A. baumanii and P. aeruginosa. Clin Infect Dis 2005;41(5):754-7
116. Quinn AL, Parada JP, Belmares J, et al. Intrathecal colistin and sterilization of resistant P. aeruginosa shunt infection. Ann Pharmacother 2005;39(5):949-52
117. Berlana D, Llop JM, Fort E, et al. Use of Colistin in the treatment of multiple drug resistant gram negative infections. Am J Health Syst Pharma 2005;62(1):39-47
118. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug resistant gram negative respiratory tract infections. J Antimicrob Chemother 2004;54(2):566-9
119. Jones RN, Feraro MJ, Reller LB, Schreckenberger PC, Swenson JM. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007;45:227-30
120. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y. VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003;9(7):868-71
121. Yong D, Choi YS, Roh KH, et al. Increasing prevalence and diversity of metallo-beta-lactamases in Pseudomonas spp., Acinetobacter spp., and Enterobacteriaceae from Korea. Antimicrob Agents Chemother 2006;50(5):1884-6
122. Iyobe S, Kusadokoro H, Ozaki J, et al. Amino acid substitutions in a variant of IMP-1 metallo-β-lactamase. Antimicrob Agents Chemother 2001;44:2023-7
123. Yano H, Kuga A, Okamoto R, Kitasato H, Kobayashi T, Inoue M. Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother 2001;45:1343-8
124. Iyobe S, Kusadokoro H, Takahashi H, et al. Detection of a variant metallo-β-lactamase, IMP-10, from two unrelated strains of P. aeruginosa and an Alcaligenes xylosoxidans strain. Antimicrob Agents Chemother 2002;46:2014-6
125. Queenan MA, Bush K. Carbapenemases: the versatile beta lactamases. Clin Microbiol Rev 2007;20(3):440-58
126. Jones RN, Biedenbath DJ, Sader HS, et al. Emerging epidemic of metallo-beta-lactamase-mediated resistance. Diagn Microbiol Infect Dis 2005;51:77-84
127. Hawkey PM, Xiong J, Ye H, Li H, M'Zail FH. Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the Peoples Republic of China. FEMS Microbiol Lett 2001;194(1):53-7
128. Wang CX, Mi ZH. IMP-1 metallo-beta-lactamase-producing Pseudomonas aeruginosa in a university hospital in the People's Republic of China. J Antimicrob Chemother 2004;54(6):1159-60
129. Wang C, Wang J, Mi Z. Pseudomonas aeruginosa producing VIM-2 metallo-beta-lactamases and carrying two aminoglycoside-modifying enzymes in China. J Hosp Infect 2006;62(4):522-4
130. Xiong J, Hynes MF, Ye H, et al. bla(IMP-9) and its association with large plasmids carried by Pseudomonas aeruginosa isolates from the Peoples Republic of China. Antimicrob Agents Chemother 2006;50(1):355-8
131. Liu SY, Lin JY, Chu C, Su LH, Lin TY, Chiu CH. Integron-associated imipenem resistance in Acinetobacter baumannii isolated from a regional hospital in Taiwan. Int J Antimicrob Agents 2006;27(1):81-4
132. Chu YW, Afzal Shah M, Houang ET, et al. IMP-4, a novel metallo-β-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother 2001;45:710-4
133. Ho Se, Subramaniam G, Palasubramaniam. S, Navaratnam P. Carbapenem-resistant P. aeruginosa in Malaysia producing IMP-7 β-lactamase. Antimicrob Agents Chemother 2002;46:3286-7.
134. Yan JJ, Ko WC, Tsai SH, Wu HM, Wu JJ. Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying blaIMP-8 in a university medical center in Taiwan. J Clin Microbiol 2001;39:4433-9
135. Yan J, Hsueh PP, Ko WC, et al. Metallo-β-lactamases in clinidal Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001;45:2224-8
136. Pournaras S, Tsakaris A, Maniati M, Tzouvelekis LS, Maniatis AN. Novel variant (blaVIM-4) of the metallo-β-lactamase gene blaVIM-1 in a clinical strain of P. aeruginosa. Antimicrob Agents Chemother 2002;46:4026-8
137. Koh TH, Wang GCY, Sng LH. IMP-1 and a novel metallo-β-lactamase, VIM-6, in fluorescent pseudomonads isolated in Singapore. Antimicrob Agents Chemother 2004;48:2334-6
138. Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-beta-lactamase-gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005;41(11):1549-56
139. Peleg AY, Franklin C, Walters LJ, Bell JM, Spelman DW. OXA-58 and IMP-4 carbapenem-hydrolyzing beta-lactamases in an Acinetobacter junii blood culture isolate from Australia. Antimicrob Agents Chemother 2006;50(1):399-400
140. Guerin F, Henegar C, Spiridon O, Latmay O, Salmon-Ceron D, Poyart C. Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-{beta}-lactamase gene from Saudi Arabia. J Antimicrob Chemother 2005;56(3):601-2
141. Navaneeth BV, Sridaran D, Sahay D, Belwadi MR. A preliminary study on metallo-beta-lactamase producing P. aeruginosa in hospitalized patients. Indian J Med Res 2002; 116:264-7
142. Joshi SG, Litake GM, Niphadkar KB, Ghole VS. Multidrug resistant Acinetobacter baumannii isolates from a reaching hospital. J Infect Chemother 2003;9(2):187-90
143. Taneja N, Maharwal S, Sharma M. Imipenem resistance in nonfermenters causing nosocomial urinary tract infections. Indian J Med Sci 2003;57(7):294-9
144. Jesudason MV, Kandathil AJ, Balaji V. Comparison of two methods to detect carbapenemase & metallo-beta-lactamase production in clinical isolates. Indian J Med Res 2005;121(6):780-3
145. Mendiratta DK, Deotale V, Narang P. Metallo-beta-lactamase producing P. aeruginosa in a hospital from a rural area. Indian J Med Res 2005;121(5):701-3
146. Hemalatha V, Sekar U, Kamat V. Detection of metallo beta lactamase producing P. aeruginosa in hospitalized patients. Indian J Med Res 2005;122(2):148-52
147. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in North India. Indian J Med Res 2006;124(1):95-8
148. Gupta V, Datta P, Chander P. Prevalence of metallo-β lactamase (MBL) producing Pseudomonas spp. and Acinetobacter spp. in a tertiary care hospital in India. J Infect 2006;52(5):311-4
149. Towner KJ, Gee T, Boswell T. An unwanted import to the UK. A carbapenem-resistant clinical isolate of Acinetobacter baumannii producing metallo-β-lactamase. J Antimicrob Chernother 2002; 50:1092-3
150. Tysall L, Stockdale ML, Chadwick PR, et al. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. J Antimicrob Chemother 2002;49:217-8
151. Sader HS, Castanheira M, Mendes RE, Toleman M, Wilsh TR, Jones RN. Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY antimicrobial surveillance program. Int J Antimicrob Agents 2005;25(1):57-61
152. Daiyasu H, Osaka K Ishino Y, Toh H. Expansion of the zinc metallo-hydrolase family of the β-lactamase fold. FEBS Lett 2001; 503:1-6
153. Gibb AP, Tribuddharat C, Moore RA, et al. Nosocomial outbreak of carbapenem-resistant P. aeruginosa. with a new blaIMP allele, blaIMP-7. Antimicrob Agents Chemother 2002;46:255-8
154. Docquier J D, Riccio ML, Mugnaioli C, et al. IMP-12, a new plasmid-encoded metallo-β-lactamase from a Pseudomonas putida clinical isolate. Antimicrob Agents Chemother 2003;47:1522-8
155. Toleman MA, Biedenbach D, Bennett D, Jones RN, Walsh TR. Genetic characterization of a novel metrallo-β-lactamase gene, blaIMP-13, harboured by-a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. J Antimicrob Chemother 2003;52:583-90
156. Hanson ND, Hossain A, Buck LL, Moland ES, Thomson KS, Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC; 2004;abstr. C1-291
157. Henrichfreise B, Wiegand I, Sherwood KJ, Wiedemann B. Detection of VIM-2 metallo-beta-lactamase in Pseudomonas aeruginosa from Germany. Antimicrob Agents Chemother 2005;49(4):1668-9
158. Dahar G, Mazzariol A, Koncan R, et al. Detection of VIM-5 metallo-beta-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey. J Antimicrob Chemother 2004;54(1):282-3
159. Libisch B, Gacs M, Csiszár K, Muzslay M, Rókusz L, Füzi M. Isolation of an integron-borne bla VIM-4 type metallo-beta-lactamase gene from a carbapenem-resistant Pseudomonas aeruginosa clinical isolate in Hungary. Antimicrob Agents Chemother 2004; 48(9):3576-8
160. Fiett J, Baraniak A, Mrówka A, et al. Molecular epidemiology of acquired-metallo-beta-lactamase-producing bacteria in Poland. Antimicrob Agents Chemother 2006;50(3):880-6
161. Toleman MA, Rolston K, Jones RN, Walsh TR. blaVIM-7, an evolutionarily distinct metallo-β-lactamase gene in a P. aeruginosa isolate from the United States. Antimicrob Agents Chemother 2004;48:329-32